Clinicopathologic characteristics of patients by somatic RET M918T, RET-other, and RET WT Status
| . | RET M918T (n = 102, A) . | RET-Other (n = 20, B) . | RET WT (n = 52, C) . | P value . | P value (A vs B) . | P value (A vs C) . | P value (B vs C) . |
|---|---|---|---|---|---|---|---|
| Age at diagnosis, median (range), y | 50 (17–83) | 60 (23–81) | 50 (11–71) | .012 | .003 | .38 | .027 |
| Female, n (%) | 56 (55) | 8 (40) | 24 (46) | .36 | .23 | .31 | .79 |
| T category at diagnosis, n (%) | .79 | .94 | .46 | .68 | |||
| T1 | 20 (20) | 4 (20) | 5 (10) | ||||
| T2 | 21 (21) | 5 (25) | 10 (19) | ||||
| T3 | 40 (39) | 8 (40) | 24 (46) | ||||
| T4 | 15 (15) | 3 (15) | 11 (21) | ||||
| TX | 6 (5) | 0 | 2 (4) | ||||
| N category at diagnosis, n (%) | .13 | .47 | .07 | .25 | |||
| N0 | 7 (7) | 0 | 8 (15) | ||||
| N1a | 8 (8) | 2 (10) | 5 (10) | ||||
| N1b | 85 (83) | 17 (85) | 35 (67) | ||||
| NX | 2 (2) | 1 (5) | 4 (8) | ||||
| M category at diagnosis, n (%) | .89 | .80 | .85 | .78 | |||
| M0 | 70 (69) | 13 (65) | 37 (71) | ||||
| M1 | 32 (31) | 7 (35) | 15 (29) | ||||
| Presence of distant metastases after diagnosis, n (%) | 37 (53) | 11 (85) | 16 (43) | .036 | .033 | .34 | .01 |
| Time from diagnosis to NGS testing, median (IQR), mo | 28.4 (7.9–67.2) | 77.2 (10.0–122.6) | 34.2 (16.6–88.7) | .21 | .14 | .24 | .33 |
| Systemic therapy, n (%)a | 65 (64) | 13 (65) | 25 (48) | .15 | .91 | .08 | .29 |
| Selective RETi | 42 (65) | 9 (69) | 0 | <.0001 | .75 | <.0001 | <.0001 |
| Nonselective MKI | 39 (60) | 8 (62) | 24 (96) | .0035 | .92 | .0006 | .012 |
| Other | 6 (9) | 1 (8) | 7 (28) | .054 | .86 | .041 | .22 |
| Time from diagnosis to systemic therapy, median (IQR), mo | 48.3 (9.4–88.3) | 51.4 (20.3–73.9) | 28.8 (14.8–89.9) | .85 | .91 | .68 | .52 |
| Death on systemic therapy, n (%) | 20 (31) | 5 (38) | 9 (36) | .81 | .59 | .63 | .88 |
| Time from systemic therapy to death, median (IQR), mo | 33.5 (11.5–45.1) | 35.6 (33.7–65.5) | 36.0 (18.8–57.0) | .63 | .45 | .53 | .80 |
| Median time to distant metastatic disease, mo (95% CI) | 101.4 (61.1–295.4) | 75.2 (32.1–168.2) | 154.0 (101.4–299.4) | .14 | .20 | .24 | .051 |
| 5-year disease-specific survival rate (%) | 85.3 | 89.2 | 85.5 | .87 | .74 | .91 | .72 |
| 5-year overall survival rate (%) | 83.8 | 89.2 | 85.5 | .96 | .82 | .94 | .75 |
| Follow-up, median (IQR), mo | 80.3 (47.2–126.5) | 96.8 (67.8–148.0) | 80.1 (58.9–136.7) | .34 | .20 | .35 | .47 |
| . | RET M918T (n = 102, A) . | RET-Other (n = 20, B) . | RET WT (n = 52, C) . | P value . | P value (A vs B) . | P value (A vs C) . | P value (B vs C) . |
|---|---|---|---|---|---|---|---|
| Age at diagnosis, median (range), y | 50 (17–83) | 60 (23–81) | 50 (11–71) | .012 | .003 | .38 | .027 |
| Female, n (%) | 56 (55) | 8 (40) | 24 (46) | .36 | .23 | .31 | .79 |
| T category at diagnosis, n (%) | .79 | .94 | .46 | .68 | |||
| T1 | 20 (20) | 4 (20) | 5 (10) | ||||
| T2 | 21 (21) | 5 (25) | 10 (19) | ||||
| T3 | 40 (39) | 8 (40) | 24 (46) | ||||
| T4 | 15 (15) | 3 (15) | 11 (21) | ||||
| TX | 6 (5) | 0 | 2 (4) | ||||
| N category at diagnosis, n (%) | .13 | .47 | .07 | .25 | |||
| N0 | 7 (7) | 0 | 8 (15) | ||||
| N1a | 8 (8) | 2 (10) | 5 (10) | ||||
| N1b | 85 (83) | 17 (85) | 35 (67) | ||||
| NX | 2 (2) | 1 (5) | 4 (8) | ||||
| M category at diagnosis, n (%) | .89 | .80 | .85 | .78 | |||
| M0 | 70 (69) | 13 (65) | 37 (71) | ||||
| M1 | 32 (31) | 7 (35) | 15 (29) | ||||
| Presence of distant metastases after diagnosis, n (%) | 37 (53) | 11 (85) | 16 (43) | .036 | .033 | .34 | .01 |
| Time from diagnosis to NGS testing, median (IQR), mo | 28.4 (7.9–67.2) | 77.2 (10.0–122.6) | 34.2 (16.6–88.7) | .21 | .14 | .24 | .33 |
| Systemic therapy, n (%)a | 65 (64) | 13 (65) | 25 (48) | .15 | .91 | .08 | .29 |
| Selective RETi | 42 (65) | 9 (69) | 0 | <.0001 | .75 | <.0001 | <.0001 |
| Nonselective MKI | 39 (60) | 8 (62) | 24 (96) | .0035 | .92 | .0006 | .012 |
| Other | 6 (9) | 1 (8) | 7 (28) | .054 | .86 | .041 | .22 |
| Time from diagnosis to systemic therapy, median (IQR), mo | 48.3 (9.4–88.3) | 51.4 (20.3–73.9) | 28.8 (14.8–89.9) | .85 | .91 | .68 | .52 |
| Death on systemic therapy, n (%) | 20 (31) | 5 (38) | 9 (36) | .81 | .59 | .63 | .88 |
| Time from systemic therapy to death, median (IQR), mo | 33.5 (11.5–45.1) | 35.6 (33.7–65.5) | 36.0 (18.8–57.0) | .63 | .45 | .53 | .80 |
| Median time to distant metastatic disease, mo (95% CI) | 101.4 (61.1–295.4) | 75.2 (32.1–168.2) | 154.0 (101.4–299.4) | .14 | .20 | .24 | .051 |
| 5-year disease-specific survival rate (%) | 85.3 | 89.2 | 85.5 | .87 | .74 | .91 | .72 |
| 5-year overall survival rate (%) | 83.8 | 89.2 | 85.5 | .96 | .82 | .94 | .75 |
| Follow-up, median (IQR), mo | 80.3 (47.2–126.5) | 96.8 (67.8–148.0) | 80.1 (58.9–136.7) | .34 | .20 | .35 | .47 |
The RET M918T group includes sMTC patients with a RET M918T mutation, the RET-Other group includes patients with other non-M918T RET mutations, and the RET WT group includes patients with RAS mutations and RET/RAS WT.
Abbreviations: IQR, interquartile range; MKI, multikinase inhibitor; NGS, next-generation sequencing; RETi, RET inhibitor; WT, wild-type.
aSelective RET inhibitors included selpercatinib and pralsetinib. Nonselective multikinase inhibitors included sorafenib, lenvatinib, sunitinib, vandetinib, and cabozantinib. Other systemic therapies included pembrolizumab, tipifarnib, everolimus, and other therapies.
Clinicopathologic characteristics of patients by somatic RET M918T, RET-other, and RET WT Status
| . | RET M918T (n = 102, A) . | RET-Other (n = 20, B) . | RET WT (n = 52, C) . | P value . | P value (A vs B) . | P value (A vs C) . | P value (B vs C) . |
|---|---|---|---|---|---|---|---|
| Age at diagnosis, median (range), y | 50 (17–83) | 60 (23–81) | 50 (11–71) | .012 | .003 | .38 | .027 |
| Female, n (%) | 56 (55) | 8 (40) | 24 (46) | .36 | .23 | .31 | .79 |
| T category at diagnosis, n (%) | .79 | .94 | .46 | .68 | |||
| T1 | 20 (20) | 4 (20) | 5 (10) | ||||
| T2 | 21 (21) | 5 (25) | 10 (19) | ||||
| T3 | 40 (39) | 8 (40) | 24 (46) | ||||
| T4 | 15 (15) | 3 (15) | 11 (21) | ||||
| TX | 6 (5) | 0 | 2 (4) | ||||
| N category at diagnosis, n (%) | .13 | .47 | .07 | .25 | |||
| N0 | 7 (7) | 0 | 8 (15) | ||||
| N1a | 8 (8) | 2 (10) | 5 (10) | ||||
| N1b | 85 (83) | 17 (85) | 35 (67) | ||||
| NX | 2 (2) | 1 (5) | 4 (8) | ||||
| M category at diagnosis, n (%) | .89 | .80 | .85 | .78 | |||
| M0 | 70 (69) | 13 (65) | 37 (71) | ||||
| M1 | 32 (31) | 7 (35) | 15 (29) | ||||
| Presence of distant metastases after diagnosis, n (%) | 37 (53) | 11 (85) | 16 (43) | .036 | .033 | .34 | .01 |
| Time from diagnosis to NGS testing, median (IQR), mo | 28.4 (7.9–67.2) | 77.2 (10.0–122.6) | 34.2 (16.6–88.7) | .21 | .14 | .24 | .33 |
| Systemic therapy, n (%)a | 65 (64) | 13 (65) | 25 (48) | .15 | .91 | .08 | .29 |
| Selective RETi | 42 (65) | 9 (69) | 0 | <.0001 | .75 | <.0001 | <.0001 |
| Nonselective MKI | 39 (60) | 8 (62) | 24 (96) | .0035 | .92 | .0006 | .012 |
| Other | 6 (9) | 1 (8) | 7 (28) | .054 | .86 | .041 | .22 |
| Time from diagnosis to systemic therapy, median (IQR), mo | 48.3 (9.4–88.3) | 51.4 (20.3–73.9) | 28.8 (14.8–89.9) | .85 | .91 | .68 | .52 |
| Death on systemic therapy, n (%) | 20 (31) | 5 (38) | 9 (36) | .81 | .59 | .63 | .88 |
| Time from systemic therapy to death, median (IQR), mo | 33.5 (11.5–45.1) | 35.6 (33.7–65.5) | 36.0 (18.8–57.0) | .63 | .45 | .53 | .80 |
| Median time to distant metastatic disease, mo (95% CI) | 101.4 (61.1–295.4) | 75.2 (32.1–168.2) | 154.0 (101.4–299.4) | .14 | .20 | .24 | .051 |
| 5-year disease-specific survival rate (%) | 85.3 | 89.2 | 85.5 | .87 | .74 | .91 | .72 |
| 5-year overall survival rate (%) | 83.8 | 89.2 | 85.5 | .96 | .82 | .94 | .75 |
| Follow-up, median (IQR), mo | 80.3 (47.2–126.5) | 96.8 (67.8–148.0) | 80.1 (58.9–136.7) | .34 | .20 | .35 | .47 |
| . | RET M918T (n = 102, A) . | RET-Other (n = 20, B) . | RET WT (n = 52, C) . | P value . | P value (A vs B) . | P value (A vs C) . | P value (B vs C) . |
|---|---|---|---|---|---|---|---|
| Age at diagnosis, median (range), y | 50 (17–83) | 60 (23–81) | 50 (11–71) | .012 | .003 | .38 | .027 |
| Female, n (%) | 56 (55) | 8 (40) | 24 (46) | .36 | .23 | .31 | .79 |
| T category at diagnosis, n (%) | .79 | .94 | .46 | .68 | |||
| T1 | 20 (20) | 4 (20) | 5 (10) | ||||
| T2 | 21 (21) | 5 (25) | 10 (19) | ||||
| T3 | 40 (39) | 8 (40) | 24 (46) | ||||
| T4 | 15 (15) | 3 (15) | 11 (21) | ||||
| TX | 6 (5) | 0 | 2 (4) | ||||
| N category at diagnosis, n (%) | .13 | .47 | .07 | .25 | |||
| N0 | 7 (7) | 0 | 8 (15) | ||||
| N1a | 8 (8) | 2 (10) | 5 (10) | ||||
| N1b | 85 (83) | 17 (85) | 35 (67) | ||||
| NX | 2 (2) | 1 (5) | 4 (8) | ||||
| M category at diagnosis, n (%) | .89 | .80 | .85 | .78 | |||
| M0 | 70 (69) | 13 (65) | 37 (71) | ||||
| M1 | 32 (31) | 7 (35) | 15 (29) | ||||
| Presence of distant metastases after diagnosis, n (%) | 37 (53) | 11 (85) | 16 (43) | .036 | .033 | .34 | .01 |
| Time from diagnosis to NGS testing, median (IQR), mo | 28.4 (7.9–67.2) | 77.2 (10.0–122.6) | 34.2 (16.6–88.7) | .21 | .14 | .24 | .33 |
| Systemic therapy, n (%)a | 65 (64) | 13 (65) | 25 (48) | .15 | .91 | .08 | .29 |
| Selective RETi | 42 (65) | 9 (69) | 0 | <.0001 | .75 | <.0001 | <.0001 |
| Nonselective MKI | 39 (60) | 8 (62) | 24 (96) | .0035 | .92 | .0006 | .012 |
| Other | 6 (9) | 1 (8) | 7 (28) | .054 | .86 | .041 | .22 |
| Time from diagnosis to systemic therapy, median (IQR), mo | 48.3 (9.4–88.3) | 51.4 (20.3–73.9) | 28.8 (14.8–89.9) | .85 | .91 | .68 | .52 |
| Death on systemic therapy, n (%) | 20 (31) | 5 (38) | 9 (36) | .81 | .59 | .63 | .88 |
| Time from systemic therapy to death, median (IQR), mo | 33.5 (11.5–45.1) | 35.6 (33.7–65.5) | 36.0 (18.8–57.0) | .63 | .45 | .53 | .80 |
| Median time to distant metastatic disease, mo (95% CI) | 101.4 (61.1–295.4) | 75.2 (32.1–168.2) | 154.0 (101.4–299.4) | .14 | .20 | .24 | .051 |
| 5-year disease-specific survival rate (%) | 85.3 | 89.2 | 85.5 | .87 | .74 | .91 | .72 |
| 5-year overall survival rate (%) | 83.8 | 89.2 | 85.5 | .96 | .82 | .94 | .75 |
| Follow-up, median (IQR), mo | 80.3 (47.2–126.5) | 96.8 (67.8–148.0) | 80.1 (58.9–136.7) | .34 | .20 | .35 | .47 |
The RET M918T group includes sMTC patients with a RET M918T mutation, the RET-Other group includes patients with other non-M918T RET mutations, and the RET WT group includes patients with RAS mutations and RET/RAS WT.
Abbreviations: IQR, interquartile range; MKI, multikinase inhibitor; NGS, next-generation sequencing; RETi, RET inhibitor; WT, wild-type.
aSelective RET inhibitors included selpercatinib and pralsetinib. Nonselective multikinase inhibitors included sorafenib, lenvatinib, sunitinib, vandetinib, and cabozantinib. Other systemic therapies included pembrolizumab, tipifarnib, everolimus, and other therapies.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
